“Budget impact analysis of dabigatran compared with rivaroxaban in the prevention of the thromboembolic risk in patients with non-valvular atrial fibrillation”, FE, vol. 18, no. 1, Nov. 2017, doi: 10.7175/fe.v18i1.1327.